Table 1 Patients characteristics.

From: Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer

 

(%)

Age (years)

< 42

8 (57)a

≥ 42

6 (43)

Menopause

Pre

10 (71)

Post

4 (29)

Histology

Not metaplastic

11 (79)

Metaplastic

3 (21)

ECOG

0

11 (79)

1

3 (21)

Prior line of therapyb

0

12 (86)

1

2 (14)

Presentation

De novo

4 (29)

Recurrent

10 (71)

  1. aPercentage of cases.
  2. bIn the metastatic setting.
Back to article page